Emerald provides Baseline tests covering more than 115 biomarkers at over 50 locations across the UK, feeds the results into a dashboard that also ingests wearable data, and layers on AI alerts plus an assigned GP who can diagnose, prescribe, and craft personalised action plans. Founded in 2024 by Alexander Badalyan with NHS clinician Dr. Daniel McNally as CMO, the company positions itself as a "Health OS" that turns fragmented data into actionable, clinically validated care. Emerald reports more than 10,000 users growing 15% month-over-month and has generated early revenues of $300,000, derived from consumer subscriptions and B2B partnerships with healthcare providers and employers. The platform claims to be the only service that seamlessly integrates with 100+ physical blood-draw locations while holding full CQC registration for clinical accountability. Recent product leadership hires, such as former Wise senior PM Susanna Raiend, strengthen execution capabilities. Looking ahead, the company plans to deepen UK penetration, launch coaching programmes in early 2026, and expand partnerships with labs, imaging centres, and corporate customers. Ultimately, Emerald aims to become the go-to clinical partner for longevity and preventative care.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2026